Part 1 (safety run‐in): Advanced, recurrent, or metastatic solid tumors with SMARCA4 mutation or SMARCA4 loss, with backfill enrichment for NSCLC with LoF SMARCA4 mutation. This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.